drugset / Trial / NCT00005950

506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma

NCT00005950

Phase 2 Terminated 111 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory non-Hodgkin's lymphoma or T-cell lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die

Timeline

Start
2000-04
Primary completion
2004-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Nelarabine Small molecule Intravenous